BG63945B1 - Тропанови производни, тяхното получаване и приложение - Google Patents
Тропанови производни, тяхното получаване и приложение Download PDFInfo
- Publication number
- BG63945B1 BG63945B1 BG102637A BG10263798A BG63945B1 BG 63945 B1 BG63945 B1 BG 63945B1 BG 102637 A BG102637 A BG 102637A BG 10263798 A BG10263798 A BG 10263798A BG 63945 B1 BG63945 B1 BG 63945B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- tropane
- dichlorophenyl
- chlorophenyl
- ethoxymethyl
- normethyl
- Prior art date
Links
- 150000003813 tropane derivatives Chemical class 0.000 title abstract description 5
- 238000002360 preparation method Methods 0.000 title description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 87
- 239000000203 mixture Substances 0.000 claims abstract description 63
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
- 208000035475 disorder Diseases 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 8
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 7
- 239000001257 hydrogen Substances 0.000 claims abstract description 7
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 5
- 150000002367 halogens Chemical group 0.000 claims abstract description 5
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 5
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims abstract description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- 125000001424 substituent group Chemical group 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 4
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 25
- 229930004006 tropane Natural products 0.000 claims description 23
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 claims description 22
- -1 2,3-trans-disubstituted tropane compound Chemical class 0.000 claims description 16
- 206010013654 Drug abuse Diseases 0.000 claims description 15
- 206010012289 Dementia Diseases 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 8
- 208000008589 Obesity Diseases 0.000 claims description 8
- 201000001272 cocaine abuse Diseases 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 8
- 208000011117 substance-related disease Diseases 0.000 claims description 8
- 208000019906 panic disease Diseases 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- PGYDXVBZYKQYCS-VPWBDBDCSA-N (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-4-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](COC)[C@]3(CC[C@@](C2)(N3C)[H])[H])=CC=C(Cl)C(Cl)=C1 PGYDXVBZYKQYCS-VPWBDBDCSA-N 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 5
- 208000030814 Eating disease Diseases 0.000 claims description 5
- 208000026097 Factitious disease Diseases 0.000 claims description 5
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 5
- 235000014632 disordered eating Nutrition 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 230000001771 impaired effect Effects 0.000 claims description 5
- 201000003631 narcolepsy Diseases 0.000 claims description 5
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000012312 sodium hydride Substances 0.000 claims description 4
- MRNJOKJVKOTTFX-KGLIPLIRSA-N (1S,5R)-1-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@]23CC[C@@](CCC2)(N3C)[H])=CC=C(Cl)C=C1 MRNJOKJVKOTTFX-KGLIPLIRSA-N 0.000 claims description 3
- UDEMPSNQARQSLU-RISCZKNCSA-N (1r,5s)-5-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@]23CC[C@@](CCC2)(N3C)[H])=CC=C(Cl)C(Cl)=C1 UDEMPSNQARQSLU-RISCZKNCSA-N 0.000 claims description 3
- HTKSGXUNQZSQKB-ZOMKSWQUSA-N (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-4-(ethylsulfanylmethyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](CSCC)[C@]3(CC[C@@](C2)(N3C)[H])[H])=CC=C(Cl)C(Cl)=C1 HTKSGXUNQZSQKB-ZOMKSWQUSA-N 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 206010052276 Pseudodementia Diseases 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- IJIHFJXJGNXNBL-FAYHIZQSSA-N (1s,5r)-3-(3,4-dichlorophenyl)-8-methyl-4-(propan-2-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound CC(C)OCC([C@]1(CC[C@@](C2)(N1C)[H])[H])C2C1=CC=C(Cl)C(Cl)=C1 IJIHFJXJGNXNBL-FAYHIZQSSA-N 0.000 claims description 2
- KXERXJFJOODRDA-ZGRYLRDCSA-N (1s,5r)-3-(4-chlorophenyl)-4-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound CCOCC([C@]1(CC[C@@](C2)(N1C)[H])[H])C2C1=CC=C(Cl)C=C1 KXERXJFJOODRDA-ZGRYLRDCSA-N 0.000 claims description 2
- IIUOULDVNOMXAP-SLTXQBBLSA-N (1s,5r)-3-(4-chlorophenyl)-4-(methoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound COCC([C@]1(CC[C@@](C2)(N1C)[H])[H])C2C1=CC=C(Cl)C=C1 IIUOULDVNOMXAP-SLTXQBBLSA-N 0.000 claims description 2
- PZUMXIMYQIJPGF-YHRBYZFPSA-N (1s,5r)-4-(cyclopropylmethoxymethyl)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@]2(CC[C@@](CC1C=1C=C(Cl)C(Cl)=CC=1)(N2C)[H])[H])COCC1CC1 PZUMXIMYQIJPGF-YHRBYZFPSA-N 0.000 claims description 2
- 208000007848 Alcoholism Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 206010028403 Mutism Diseases 0.000 claims description 2
- 206010029333 Neurosis Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 206010043903 Tobacco abuse Diseases 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- DMLFJMQTNDSRFU-UHFFFAOYSA-N chlordiazepoxide hydrochloride Chemical compound Cl.O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 DMLFJMQTNDSRFU-UHFFFAOYSA-N 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 208000015238 neurotic disease Diseases 0.000 claims description 2
- 206010036596 premature ejaculation Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000002271 trichotillomania Diseases 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- WRSAWSIAUHZZJR-MKCYZYCBSA-N (1s,5r)-3-(4-chlorophenyl)-4-(cyclopropylmethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@]2(CC[C@@](CC1C=1C=CC(Cl)=CC=1)(N2C)[H])[H])COCC1CC1 WRSAWSIAUHZZJR-MKCYZYCBSA-N 0.000 claims 1
- 206010052804 Drug tolerance Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 230000026781 habituation Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007074 memory dysfunction Effects 0.000 claims 1
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract description 23
- 239000002858 neurotransmitter agent Substances 0.000 abstract description 18
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 18
- 229960003638 dopamine Drugs 0.000 abstract description 14
- 230000005764 inhibitory process Effects 0.000 abstract description 13
- 229960002748 norepinephrine Drugs 0.000 abstract description 9
- 229940076279 serotonin Drugs 0.000 abstract description 9
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract description 8
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract description 8
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 46
- 239000000243 solution Substances 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- 239000004480 active ingredient Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 11
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 11
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000009870 specific binding Effects 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 8
- 239000008346 aqueous phase Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 6
- 208000027089 Parkinsonian disease Diseases 0.000 description 5
- 206010034010 Parkinsonism Diseases 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 239000000935 antidepressant agent Substances 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 4
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
- 208000020925 Bipolar disease Diseases 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 239000007818 Grignard reagent Substances 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 229940005513 antidepressants Drugs 0.000 description 4
- 229960003920 cocaine Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000004744 fabric Substances 0.000 description 4
- 150000004795 grignard reagents Chemical class 0.000 description 4
- 238000005567 liquid scintillation counting Methods 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 210000003568 synaptosome Anatomy 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 3
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 102000010909 Monoamine Oxidase Human genes 0.000 description 3
- 108010062431 Monoamine oxidase Proteins 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000000946 synaptic effect Effects 0.000 description 3
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 2
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- APSMUYYLXZULMS-UHFFFAOYSA-N 2-bromonaphthalene Chemical compound C1=CC=CC2=CC(Br)=CC=C21 APSMUYYLXZULMS-UHFFFAOYSA-N 0.000 description 2
- SVDDJQGVOFZBNX-UHFFFAOYSA-N 2-chloroethyl carbonochloridate Chemical compound ClCCOC(Cl)=O SVDDJQGVOFZBNX-UHFFFAOYSA-N 0.000 description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- MPSNEAHFGOEKBI-VXNVDRBHSA-N Anhydroecgonine methyl ester Chemical compound COC(=O)C1=CC[C@@H]2CC[C@H]1N2C MPSNEAHFGOEKBI-VXNVDRBHSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- SQHYCNHBKWYMFN-FHFGAJOLSA-N [(1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-4-yl]methanol;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1([C@@H]2[C@@H](CO)[C@]3(CC[C@@](C2)(N3C)[H])[H])=CC=C(Cl)C(Cl)=C1 SQHYCNHBKWYMFN-FHFGAJOLSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229960004424 carbon dioxide Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960001653 citalopram Drugs 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 229960003914 desipramine Drugs 0.000 description 2
- 230000002825 dopamine reuptake Effects 0.000 description 2
- 230000028436 dopamine uptake Effects 0.000 description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000006317 isomerization reaction Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- RLLMNWXOZDXKCQ-KSUSIZLGSA-N methyl (1R,5S)-3-hydroxy-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate hydrochloride Chemical compound Cl.COC(=O)C1[C@H]2CC[C@@H](CC1O)N2C RLLMNWXOZDXKCQ-KSUSIZLGSA-N 0.000 description 2
- WXEMSGQRTGSYOG-PMDVUHRTSA-N methyl (1s,5r)-8-methyl-3-oxo-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C1C(=O)C(C(=O)OC)[C@@]2([H])CC[C@]1([H])N2C WXEMSGQRTGSYOG-PMDVUHRTSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 230000000697 serotonin reuptake Effects 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- QUSLQENMLDRCTO-YJNKXOJESA-N win 35428 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(F)C=C1 QUSLQENMLDRCTO-YJNKXOJESA-N 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- JRHMVKIEZPGESJ-OSGXGRJZSA-N (1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-8-methyl-4-[(4-methylphenyl)sulfonylmethyl]-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1[C@]2(CC[C@@](C[C@@H]1C=1C=C(Cl)C(Cl)=CC=1)(N2C)[H])[H])S(=O)(=O)C1=CC=C(C)C=C1 JRHMVKIEZPGESJ-OSGXGRJZSA-N 0.000 description 1
- KXERXJFJOODRDA-YLFCFFPRSA-N (1s,3s,4r,5r)-3-(4-chlorophenyl)-4-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](COCC)[C@]3(CC[C@@](C2)(N3C)[H])[H])=CC=C(Cl)C=C1 KXERXJFJOODRDA-YLFCFFPRSA-N 0.000 description 1
- JFKDALFTVGTCNQ-YOGCLGLASA-N (1s,5r)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@]1(CC[C@@](C2)(N1C)[H])[H])C2C1=CC=C(Cl)C(Cl)=C1 JFKDALFTVGTCNQ-YOGCLGLASA-N 0.000 description 1
- QEHZKRWVYAVCDB-QXMXGUDHSA-N (1s,5r)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@]1(CC[C@@](C2)(N1C)[H])[H])C2C1=CC=C(Cl)C=C1 QEHZKRWVYAVCDB-QXMXGUDHSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- GOFIUEUUROFVMA-UHFFFAOYSA-N 1-(1h-indol-5-yl)ethanone Chemical compound CC(=O)C1=CC=C2NC=CC2=C1 GOFIUEUUROFVMA-UHFFFAOYSA-N 0.000 description 1
- AITNMTXHTIIIBB-UHFFFAOYSA-N 1-bromo-4-fluorobenzene Chemical compound FC1=CC=C(Br)C=C1 AITNMTXHTIIIBB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IXVAXSYRPPGIAQ-ZRJGNOHYSA-N C(=O)(OC)[C@@]12C(C(C[C@H](CC1)N2C)O)=O Chemical compound C(=O)(OC)[C@@]12C(C(C[C@H](CC1)N2C)O)=O IXVAXSYRPPGIAQ-ZRJGNOHYSA-N 0.000 description 1
- XTSCVMBKKFMLQC-HKJUDDBKSA-N C(=O)(OC)[C@]12CC(C[C@H](CC1)N2C)O Chemical compound C(=O)(OC)[C@]12CC(C[C@H](CC1)N2C)O XTSCVMBKKFMLQC-HKJUDDBKSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- NVHBMINFKCGBNN-BTXUNPJVSA-N Cl.C(=O)(OC)[C@H]1[C@H]2CC[C@@H](C[C@@H]1CC1=CC=CC=C1)N2C Chemical compound Cl.C(=O)(OC)[C@H]1[C@H]2CC[C@@H](C[C@@H]1CC1=CC=CC=C1)N2C NVHBMINFKCGBNN-BTXUNPJVSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- KIWBPDUYBMNFTB-UHFFFAOYSA-N Ethyl hydrogen sulfate Chemical compound CCOS(O)(=O)=O KIWBPDUYBMNFTB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 239000004826 Synthetic adhesive Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YZOJGDVBJLRATM-FUTJPDQTSA-N [(1s,3s,4r,5r)-3-(3,4-dichlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-4-yl]methanol Chemical compound C1([C@@H]2[C@@H](CO)[C@]3(CC[C@@](C2)(N3C)[H])[H])=CC=C(Cl)C(Cl)=C1 YZOJGDVBJLRATM-FUTJPDQTSA-N 0.000 description 1
- CZRLQYHGYBWJCU-GBJTYRQASA-N [(1s,3s,4r,5r)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-4-yl]methanol Chemical compound C1([C@@H]2[C@@H](CO)[C@]3(CC[C@@](C2)(N3C)[H])[H])=CC=C(F)C=C1 CZRLQYHGYBWJCU-GBJTYRQASA-N 0.000 description 1
- CZRLQYHGYBWJCU-LJISPDSOSA-N [(1s,3s,4s,5r)-3-(4-fluorophenyl)-8-methyl-8-azabicyclo[3.2.1]octan-4-yl]methanol Chemical compound C1([C@@H]2[C@H](CO)[C@]3(CC[C@@](C2)(N3C)[H])[H])=CC=C(F)C=C1 CZRLQYHGYBWJCU-LJISPDSOSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- MPSNEAHFGOEKBI-UHFFFAOYSA-N anhydroecogonine methyl ester Natural products COC(=O)C1=CCC2CCC1N2C MPSNEAHFGOEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- PIQVDUKEQYOJNR-VZXSFKIWSA-N cocaine hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@H]2CC[C@@H]([NH+]2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 PIQVDUKEQYOJNR-VZXSFKIWSA-N 0.000 description 1
- 229960003771 cocaine hydrochloride Drugs 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000001653 corpus striatum Anatomy 0.000 description 1
- 210000005080 cortical synaptosome Anatomy 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 150000002431 hydrogen Chemical group 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000002117 illicit drug Substances 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- YHWZJYKIOUHJGH-CAOSSQGBSA-N methyl (1s,3s,4r,5r)-3-benzyl-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C([C@@H]1[C@H]([C@]2(CC[C@@](C1)(N2C)[H])[H])C(=O)OC)C1=CC=CC=C1 YHWZJYKIOUHJGH-CAOSSQGBSA-N 0.000 description 1
- YHWZJYKIOUHJGH-JONQDZQNSA-N methyl (1s,3s,4s,5r)-3-benzyl-8-methyl-8-azabicyclo[3.2.1]octane-4-carboxylate Chemical compound C([C@@H]1[C@@H]([C@]2(CC[C@@](C1)(N2C)[H])[H])C(=O)OC)C1=CC=CC=C1 YHWZJYKIOUHJGH-JONQDZQNSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000000407 monoamine reuptake Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000001561 neurotransmitter reuptake Effects 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- QMYDVDBERNLWKB-UHFFFAOYSA-N propane-1,2-diol;hydrate Chemical compound O.CC(O)CO QMYDVDBERNLWKB-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229960002601 protriptyline Drugs 0.000 description 1
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000013275 serotonin uptake Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BZWKPZBXAMTXNQ-UHFFFAOYSA-N sulfurocyanidic acid Chemical compound OS(=O)(=O)C#N BZWKPZBXAMTXNQ-UHFFFAOYSA-N 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK19496 | 1996-02-22 | ||
| PCT/EP1997/000850 WO1997030997A1 (en) | 1996-02-22 | 1997-02-21 | Tropane-derivatives, their preparation and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG102637A BG102637A (en) | 1999-06-30 |
| BG63945B1 true BG63945B1 (bg) | 2003-07-31 |
Family
ID=8090830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG102637A BG63945B1 (bg) | 1996-02-22 | 1998-07-15 | Тропанови производни, тяхното получаване и приложение |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US6288079B1 (cs) |
| EP (2) | EP1130020A1 (cs) |
| JP (1) | JP3238414B2 (cs) |
| KR (1) | KR100446571B1 (cs) |
| CN (1) | CN1077574C (cs) |
| AT (1) | ATE203023T1 (cs) |
| AU (1) | AU720358B2 (cs) |
| BG (1) | BG63945B1 (cs) |
| BR (1) | BR9707636A (cs) |
| CA (1) | CA2244773C (cs) |
| CZ (1) | CZ287007B6 (cs) |
| DE (1) | DE69705608T2 (cs) |
| DK (1) | DK0885220T3 (cs) |
| EE (1) | EE04751B1 (cs) |
| ES (1) | ES2159839T3 (cs) |
| GR (1) | GR3036829T3 (cs) |
| HU (1) | HU228356B1 (cs) |
| IL (1) | IL125146A (cs) |
| IS (1) | IS1824B (cs) |
| NO (1) | NO318731B1 (cs) |
| NZ (1) | NZ330886A (cs) |
| PL (1) | PL185132B1 (cs) |
| PT (1) | PT885220E (cs) |
| RU (1) | RU2167876C2 (cs) |
| SG (1) | SG99853A1 (cs) |
| SI (1) | SI0885220T1 (cs) |
| SK (1) | SK281813B6 (cs) |
| TR (1) | TR199801641T2 (cs) |
| UA (1) | UA49872C2 (cs) |
| WO (1) | WO1997030997A1 (cs) |
| ZA (1) | ZA971525B (cs) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2356225T3 (es) * | 1998-09-30 | 2011-04-06 | Nihon Medi-Physics Co., Ltd. | Procedimiento para producir un derivado de ácido tropinona-monocarboxílico ópticamente activo. |
| AUPP627498A0 (en) | 1998-10-02 | 1998-10-22 | University Of Queensland, The | Novel peptides - i |
| US20040106643A1 (en) * | 2001-05-23 | 2004-06-03 | Gouliaev Alex Haarh | Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CA2506646A1 (en) * | 2001-10-11 | 2003-04-11 | Organix, Inc. | Serotonin transport inhibitors |
| US20030114475A1 (en) * | 2001-10-31 | 2003-06-19 | Addiction Therapies, Inc. | Methods for the treatment of addiction |
| EP1453511B1 (en) * | 2001-11-30 | 2006-11-15 | Neurosearch A/S | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases |
| NZ536415A (en) * | 2002-05-30 | 2006-10-27 | Neurosearch As | Triple monoamine reuptake inhibitors for the treatment of chronic pain |
| ATE461174T1 (de) | 2002-11-01 | 2010-04-15 | Neurosearch As | Neue piperidinderivate und deren verwendung als monoaminneurotransmitter-wiederaufnahmehemmer |
| JP4565087B2 (ja) | 2002-12-02 | 2010-10-20 | ゼノム リミティッド | 新規なχ−コノトキシン・ペプチド（−Ｉ） |
| EP2386566A3 (en) | 2002-12-02 | 2012-02-15 | Xenome Ltd | Chi-conotoxin peptides (II) |
| JP2006517567A (ja) | 2003-02-12 | 2006-07-27 | ニューロサーチ、アクティーゼルスカブ | 新規８−アザ−ビシクロ［３．２．１］オクタン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法 |
| CN100551924C (zh) * | 2003-02-12 | 2009-10-21 | 神经研究公司 | 8-氮杂-双环[3.2.1]辛烷衍生物和它们作为单胺神经递质再摄取抑制剂的用途 |
| NZ541249A (en) | 2003-02-12 | 2008-04-30 | Neurosearch As | Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| CN100372850C (zh) * | 2003-02-12 | 2008-03-05 | 神经研究公司 | 新的8-氮杂-双环[3.2.1]辛烷衍生物和它们作为单胺神经递质再摄取抑制剂的用途 |
| CA2530023A1 (en) | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Novel 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AR045141A1 (es) * | 2003-07-31 | 2005-10-19 | Neurosearch As | Sales de tartrato de 2- metoximetil-3-(3,4-diclorofenil)-8-azabiciclo (3,2,1) octano. composiciones farmaceuticas que los contienen y usos de las mismas. |
| ATE380813T1 (de) | 2003-10-03 | 2007-12-15 | Pfizer | Imidazopyridinsubstituierte tropanderivate mit ccr5-rezeptorantagonistischer wirkung zur behandlung von hiv und entzündungen |
| CA2542442C (en) * | 2003-10-16 | 2012-08-21 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor |
| JP2007511559A (ja) * | 2003-11-18 | 2007-05-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固形医薬製剤 |
| WO2005070427A1 (en) | 2004-01-22 | 2005-08-04 | Neurosearch A/S | Compounds for the sustained reduction of body weight |
| WO2005070428A1 (en) * | 2004-01-22 | 2005-08-04 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist |
| EP1708707A1 (en) * | 2004-01-22 | 2006-10-11 | Neurosearch A/S | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist |
| DE102004004965B4 (de) * | 2004-01-31 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung eines 2-(Ethoxymethyl)-tropanderivates |
| EP1755602A1 (en) * | 2004-06-04 | 2007-02-28 | Neurosearch A/S | Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid (a beta 40 and a beta 42) generation |
| EP1761493A2 (en) | 2004-06-18 | 2007-03-14 | Neurosearch A/S | Alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US7524958B2 (en) | 2004-06-18 | 2009-04-28 | Neurosearch A/S | Certain 9-aza-bicyclo[3.3.1] nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| EP1761527A1 (en) * | 2004-06-18 | 2007-03-14 | Neurosearch A/S | Novel 9-aza-bicyclo¬3.3.1|nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| MX2007002384A (es) | 2004-09-30 | 2007-05-11 | Neurosearch As | Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina. |
| WO2006035034A1 (en) * | 2004-09-30 | 2006-04-06 | Neurosearch A/S | Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US7923444B2 (en) | 2005-02-10 | 2011-04-12 | Neurosearch A/S | Alkyl substituted homopiperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US7704991B2 (en) * | 2005-04-04 | 2010-04-27 | Neurosearch A/S | Substituted diazabicyclo derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| JP2008534653A (ja) | 2005-04-08 | 2008-08-28 | ノイロサーチ アクティーゼルスカブ | 新規エナンチオマー及びモノアミン神経伝達物質再取り込み阻害剤としてのそれらの使用 |
| US8093388B2 (en) * | 2005-06-28 | 2012-01-10 | Neurosearch A/S | 3-aza spiro[5,5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| EP1899301B1 (en) * | 2005-06-28 | 2010-09-15 | NeuroSearch A/S | Novel 3-aza-spiro[5.5]undec-8-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| JP2008546826A (ja) * | 2005-06-28 | 2008-12-25 | ノイロサーチ アクティーゼルスカブ | 新規な３，９−ジアザ−スピロ［５．５］ウンデカン誘導体及びモノアミン神経伝達物質再取り込み阻害剤としてのこれらの使用 |
| EP1899303B1 (en) * | 2005-06-28 | 2010-09-15 | NeuroSearch A/S | Novel 3-aza-spiro[5.5]undecane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| JP2009500440A (ja) * | 2005-07-12 | 2009-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 性欲障害治療用医薬組成物 |
| BRPI0613403A2 (pt) | 2005-07-15 | 2009-02-10 | Amr Technology Inc | tetrahidrobenzodiazepinas aril- e heteroarila-substituÍdas e uso das mesmas para bloquear a recaptaÇço de norepinefrina, dopamina e serotonina |
| US8383817B2 (en) * | 2005-08-24 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Benztropine compounds and uses thereof |
| WO2007028769A1 (en) * | 2005-09-05 | 2007-03-15 | Neurosearch A/S | Monoamine neurotransmitter re-uptake inhibitor for neuroprotection |
| WO2007028770A1 (en) * | 2005-09-05 | 2007-03-15 | Neurosearch A/S | Monoamine neurotransmitter re-uptake inhibitors for neuroprotection in patients suffering from an advanced stage of a mental disease |
| EP1779851A1 (en) | 2005-10-31 | 2007-05-02 | Boehringer Ingelheim Pharma GmbH & Co.KG | Treatment of diabetes |
| TW200804367A (en) * | 2005-11-11 | 2008-01-16 | Neurosearch As | Novel compounds |
| CA2641678A1 (en) | 2006-02-10 | 2007-08-16 | Neurosearch A/S | 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| TW200800980A (en) * | 2006-02-17 | 2008-01-01 | Neurosearch As | Novel compounds |
| US20100234349A1 (en) | 2006-09-04 | 2010-09-16 | Olsen Gunnar M | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| EA200970266A1 (ru) * | 2006-09-11 | 2009-08-28 | Глэксо Груп Лимитед | Азабициклические соединения в качестве ингибиторов повторного поглощения моноаминов |
| GB0703998D0 (en) * | 2007-03-01 | 2007-04-11 | Glaxo Group Ltd | Novel salt |
| TW200904815A (en) | 2007-05-09 | 2009-02-01 | Neurosearch As | Novel compounds |
| JP2010539075A (ja) * | 2007-09-10 | 2010-12-16 | ノイロサーチ アクティーゼルスカブ | フェノキサジン−３−オンの新規誘導体、並びにモノアミン神経伝達物質再取り込み阻害剤としてのその使用 |
| US20100286195A1 (en) * | 2007-09-10 | 2010-11-11 | Neurosearch A/S | Novel benzooxazol-and benzooxathiol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| EP2222303A1 (en) * | 2007-11-20 | 2010-09-01 | NeuroSearch A/S | A method for treating addiction |
| US20110118304A1 (en) * | 2007-11-20 | 2011-05-19 | Neurosearch A/S | Method for treating over-eating disorders |
| AU2010247735B2 (en) | 2009-05-12 | 2015-07-16 | Albany Molecular Research, Inc. | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof |
| ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
| US8697721B2 (en) | 2009-05-15 | 2014-04-15 | Aniona Aps | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2011032903A1 (en) | 2009-09-21 | 2011-03-24 | Neurosearch A/S | Piperazinyl-alkyl-benzoimidazol-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US20130040985A1 (en) | 2010-01-29 | 2013-02-14 | Neurosearch A/S | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2011117289A1 (en) | 2010-03-25 | 2011-09-29 | Neurosearch A/S | Chromen-2-one derivatives and their use as monoamine neuro-transmitter re-uptake inhibitors |
| US8153653B2 (en) * | 2010-06-22 | 2012-04-10 | Hoffmann-La Roche Inc. | Amido-tropane derivatives |
| WO2012000881A1 (en) | 2010-07-02 | 2012-01-05 | Neurosearch A/S | Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| US9045468B2 (en) | 2010-08-17 | 2015-06-02 | Albany Molecular Research, Inc. | 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| MX2013003749A (es) | 2010-10-07 | 2013-05-09 | Takeda Pharmaceutical | Derivados de 1,4-oxazepano. |
| CN108434129A (zh) | 2012-02-16 | 2018-08-24 | 萨尼奥纳有限责任公司 | 用于联合治疗的药物组合物 |
| EP3265126B1 (en) | 2015-03-03 | 2021-06-02 | Saniona A/S | Tesofensine and metoprolol combination formulation |
| EA026727B1 (ru) * | 2015-09-10 | 2017-05-31 | Замертон Холдингс Лимитед | Соль (1r,2r,3s)-3-(3,4-дихлорфенил)-2-(этоксиметил)-8-метил-8-азабицикло[3.2.1]октана и фталевой кислоты, способ её получения, продукт способа, фармацевтические композиции для лечения и/или профилактики нарушений, связанных с ожирением, их применение и способы лечения и/или профилактики нарушений, связанных с ожирением |
| WO2017121432A1 (en) | 2016-01-15 | 2017-07-20 | Saniona A/S | Tesofensine and metoprolol for treatment of hypertension |
| EA028995B1 (ru) * | 2016-02-25 | 2018-01-31 | Замертон Холдингс Лимитед | Соль тезофензина и оптически активных ацетиламинокислот, их применение для лечения и/или профилактики нарушений, связанных с ожирением |
| AU2017324406A1 (en) * | 2016-09-07 | 2019-05-02 | Saniona A/S | Tesofensine compositions |
| DE102017210141A1 (de) | 2017-06-16 | 2018-12-20 | Henkel Ag & Co. Kgaa | Portion zur Bereitstellung tensidhaltiger Flotten |
| US20220160658A1 (en) | 2019-01-07 | 2022-05-26 | Saniona A/S | Tesofensine for reduction of body weight in prader-willi patients |
| EP4138830A1 (en) | 2020-04-22 | 2023-03-01 | Saniona A/S | Treatment of hypothalamic obesity |
| TWI772928B (zh) * | 2020-10-21 | 2022-08-01 | 行政院原子能委員會核能研究所 | 非放射性標準品β-CFT之製備方法 |
| CN119584965A (zh) | 2022-07-08 | 2025-03-07 | 创始人制药股份有限公司 | 治疗女性性功能异常的化合物 |
| CN115572289A (zh) * | 2022-10-24 | 2023-01-06 | 龙曦宁（上海）医药科技有限公司 | 一种特索芬辛的合成方法 |
| IL319787A (en) | 2022-10-28 | 2025-05-01 | Initiator Pharma As | Compound for pain treatment |
| WO2024146892A1 (en) | 2023-01-03 | 2024-07-11 | Initiator Pharma A/S | Compound for treatment of erectile dysfunction |
| WO2025051846A1 (en) | 2023-09-05 | 2025-03-13 | Initiator Pharma A/S | Compound for treatment of female sexual dysfunction |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4281130A (en) * | 1979-05-24 | 1981-07-28 | Sterling Drug Inc. | Lower-alkyl 4,6,7,8,8a-9-hexahydro-6,9-ethanothieno[3,2-f]indolizine-10-carboxylate |
| US5496953A (en) | 1990-08-09 | 1996-03-05 | Research Triangle Institute | Cocaine receptor binding ligands |
| US5380848A (en) * | 1990-08-09 | 1995-01-10 | Research Triangle Institute | Cocaine receptor binding ligands |
| US5128118A (en) | 1990-08-09 | 1992-07-07 | Research Triangle Institute | Cocaine receptor binding ligands |
| KR100251339B1 (ko) * | 1991-11-15 | 2000-09-01 | 제임스 씨. 하이트 | 코카인 수용체 결합 리간드 |
| AU672052B2 (en) | 1992-12-23 | 1996-09-19 | Neurosearch A/S | Antidepressant and antiparkinsonian compounds |
| AU672644B2 (en) * | 1992-12-23 | 1996-10-10 | Neurosearch A/S | Aryl substituted heterocyclic compounds |
| AU671163B2 (en) * | 1992-12-23 | 1996-08-15 | Neurosearch A/S | Alkyl substituted heterocyclic compounds |
| CZ284379B6 (cs) * | 1994-04-19 | 1998-11-11 | Neurosearch A/S | Tropanové deriváty, způsob jejich přípravy a jejich použití |
| GB9626611D0 (en) * | 1996-12-20 | 1997-02-05 | Unilever Plc | Agglomerated silicas |
-
1997
- 1997-02-21 SI SI9730163T patent/SI0885220T1/xx unknown
- 1997-02-21 EP EP01108256A patent/EP1130020A1/en not_active Withdrawn
- 1997-02-21 AU AU17940/97A patent/AU720358B2/en not_active Ceased
- 1997-02-21 ZA ZA9701525A patent/ZA971525B/xx unknown
- 1997-02-21 KR KR10-1998-0706518A patent/KR100446571B1/ko not_active Expired - Fee Related
- 1997-02-21 SG SG9903902A patent/SG99853A1/en unknown
- 1997-02-21 UA UA98073814A patent/UA49872C2/uk unknown
- 1997-02-21 CN CN97192505A patent/CN1077574C/zh not_active Expired - Fee Related
- 1997-02-21 PT PT97903355T patent/PT885220E/pt unknown
- 1997-02-21 BR BR9707636A patent/BR9707636A/pt not_active IP Right Cessation
- 1997-02-21 JP JP52981097A patent/JP3238414B2/ja not_active Expired - Fee Related
- 1997-02-21 SK SK929-98A patent/SK281813B6/sk not_active IP Right Cessation
- 1997-02-21 NZ NZ330886A patent/NZ330886A/xx not_active IP Right Cessation
- 1997-02-21 IL IL12514697A patent/IL125146A/en not_active IP Right Cessation
- 1997-02-21 DE DE69705608T patent/DE69705608T2/de not_active Expired - Lifetime
- 1997-02-21 WO PCT/EP1997/000850 patent/WO1997030997A1/en active IP Right Grant
- 1997-02-21 ES ES97903355T patent/ES2159839T3/es not_active Expired - Lifetime
- 1997-02-21 EE EE9800254A patent/EE04751B1/xx not_active IP Right Cessation
- 1997-02-21 AT AT97903355T patent/ATE203023T1/de active
- 1997-02-21 PL PL97328503A patent/PL185132B1/pl not_active IP Right Cessation
- 1997-02-21 US US09/101,524 patent/US6288079B1/en not_active Expired - Lifetime
- 1997-02-21 CZ CZ19982520A patent/CZ287007B6/cs not_active IP Right Cessation
- 1997-02-21 TR TR1998/01641T patent/TR199801641T2/xx unknown
- 1997-02-21 EP EP97903355A patent/EP0885220B1/en not_active Expired - Lifetime
- 1997-02-21 CA CA002244773A patent/CA2244773C/en not_active Expired - Lifetime
- 1997-02-21 RU RU98117314/04A patent/RU2167876C2/ru active
- 1997-02-21 DK DK97903355T patent/DK0885220T3/da active
- 1997-02-21 HU HU9901199A patent/HU228356B1/hu not_active IP Right Cessation
-
1998
- 1998-07-15 BG BG102637A patent/BG63945B1/bg unknown
- 1998-08-17 IS IS4825A patent/IS1824B/is unknown
- 1998-08-21 NO NO19983877A patent/NO318731B1/no not_active IP Right Cessation
-
2001
- 2001-03-21 US US09/814,413 patent/US6395748B2/en not_active Expired - Fee Related
- 2001-10-08 GR GR20010401690T patent/GR3036829T3/el unknown
-
2002
- 2002-03-15 US US10/099,642 patent/US20020128284A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG63945B1 (bg) | Тропанови производни, тяхното получаване и приложение | |
| KR100277482B1 (ko) | 신경전달물질 재흡수 저해제인 융합구조의 트로판 유도체 | |
| EP1339406B1 (en) | Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders | |
| US6759405B2 (en) | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | |
| LV11738B (en) | Tropane-2-aldoxime derivatives as neurotransmitter reuptake inhibitors | |
| IE52649B1 (en) | Octahydrobenzo(f)quinoline compounds | |
| US6057321A (en) | 1,4-diazabicyclo [2.2.2] oct-2-ylmethyl derivatives, their preparation and therapeutic application | |
| GB2120662A (en) | New azepinoindoles, their production and pharmaceutical compositions containing them | |
| JP2719063B2 (ja) | 置換３−アミノキヌクリジンｐ物質拮抗剤 | |
| JP2010536919A (ja) | ノルエピネフリン、セロトニンまたはドーパミン再取り込み阻害剤として有用な３−アザビシクロ（４．１．０）ヘプタン誘導体 | |
| JPH08502293A (ja) | 認識疾患の治療に有用な３，３−ジ置換された三環式および四環式インドリン−２−オン | |
| MXPA98003554A (en) | Frozen tropan derivatives, its preparation and | |
| HK1057864B (en) | Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |